Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questions Linger Over Coverage-With-Evidence-Development Guidance

This article was originally published in The Gray Sheet

Executive Summary

CMS' latest direction on coverage with evidence development has small manufacturers still guessing how far the agency intends to extend its oversight and how much of the burden of fulfilling CMS' goals will fall to firms

You may also be interested in...



Bioethicists Advocate Cost Criterion For Coverage With Evidence Development

Pricier medical technologies might be better candidates for Medicare coverage conditioned on collection of evidence than less costly products, National Institutes of Health bioethicists suggest

Bioethicists Advocate Cost Criterion For Coverage With Evidence Development

Pricier medical technologies might be better candidates for Medicare coverage conditioned on collection of evidence than less costly products, National Institutes of Health bioethicists suggest

CMS Should Clarify Coverage For Device Trials, Manufacturers Say

Device manufacturers are asking for a clearer path to Medicare coverage of their clinical studies

Related Content

UsernamePublicRestriction

Register

MT023906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel